Treatment of Upper Extremity Deep-Vein Thrombosis

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to document the long-term outcome or prognosis of patients diagnosed with upper extremity deep-vein thrombosis who are treated with Fragmin (dalteparin sodium injection) for three months.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Oklahoma
• Collaborator: Pfizer
• Treatments: Dalteparin; Heparin, Low-Molecular-Weight; Tinzaparin; Warfarin

Criteria

Inclusion Criteria:

• Patients with confirmed upper extremity DVT diagnosed by ultrasound imaging or venogram

Exclusion Criteria:

• Active, clinically significant bleeding

• Known hypersensitivity to heparin or low-molecular weight heparin

• Currently pregnant or less than 1 week post-partum

• Acquired bleeding diathesis

• Known inherited bleeding disorder

• Renal failure

• Extremes of weight

• Poor performance status

• Unable to return for repeat diagnostic testing or follow-up visits